BioCryst Pharmaceuticals
BCRX
BCRX
241 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
241
Holders Change
+3
Holders Change %
+1.26%
% of All Funds
3.51%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
43
Increased
83
Reduced
69
Closed
38
Calls
$8.76M
Puts
$9.04M
Net Calls
-$281K
Net Calls Change
+$1.22M
Top Buyers
| 1 |
CP
Caligan Partners
New York
|
$28.4M |
| 2 |
DM
Deerfield Management
New York
|
$50.3M |
| 3 |
Alkeon Capital Management
New York
|
$43.9M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
$54.5M |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
$27.8M |
